Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (March 2021)
13 slides from Astrazeneca's investor day presentation, Mar 25, 2021
Slide 1: New CVRM: emerging pipeline
Break-out session 1 New CVRM: emerging pipeline Regina Fritsche Danielson, Senior Vice President, early-stage R&D Tomas Andersson, Vice President, late-stage R&D Lori Kreamer, Vice President, CVRM, BioPharmaceuticals Business Unit 25 March 2021 Interactive event for investors and analysts. This webi
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Bold ambitions in four disease areas with prioritised medicines
Bold ambitions in four disease areas with prioritised medicines Cardiovascular Heart failure Renal Metabolism Liver disease Reverse atherosclerosis to Eliminate hospitalisations Eliminate dialysis Cure diabetes halt morbidity and prolong life and cure HFrEF5 Eliminate NASH14 17.9 million 64 million
Slide 4: AZD8233: PCSK9 ASO
AZD8233: PCSK9 ASO Potential for improved efficacy with convenient at-home administration Up to 90% PCSK9 inhibition Up to 70% reduction of LDL2 for six weeks in Phase I SAD1 cholesterol in Phase I SAD 20 mg PCSK9 change from baseline (%) LDL-C change from baseline (%) 30 mg 20 mg 30 mg 60 mg 60 mg
Slide 5: AZD4831: small-molecule MPO inhibitor
AZD4831: small-molecule MPO inhibitor Targeting blood vessels inflammation and fibrosis PROMIS observational Trend towards Improved quality Reduced trial in HFpEF patients 6MWD improvement of life at day 90 NT-proBNP3 6 min walk distance (meters) P = 0.036 6 min walk distance (meters) 400 R2 = 0,072
Slide 6: Farxiga: novel, fixed-dose combinations
Farxiga: novel, fixed-dose combinations AZD9977 and zibotentan combos with opportunity to enhance efficacy Rodent model: AZD9977 Rodent model: AZD9977 SONAR3 post hoc sub-analysis improved cardiac had a predicted reduced DELIGHT trial data: Farxiga effect on BW (left) and uACR (right) function simil
Slide 7: Cotadutide: dual glucagon and GLP-1 receptor agonist
Cotadutide: dual glucagon and GLP-1 receptor agonist Promising efficacy in overweight T2D1 patients with fatty liver Mechanism of action at target organs Reduced liver fat Reduced liver fibrosis after four weeks after 54 weeks Relative change from baseline in liver Absolute change from baseline of l
Slide 8: Full pipeline and news flow
Full pipeline and news flow Upcoming milestones and expanding pipeline New CVRM: emerging pipeline Upcoming milestones Phase IIa/b data readouts Phase I Phase II H1 2021 AZD2373 AZD4831 MEDI6012 (APOL-11) (MPO) (LCAT8) • AZD5718 - CAD12 podocyte health nephropathy HFpEF CV disease AZD2693 AZ5718 MED
Slide 9: Questions & Answers
Questions & Answers To ask a question Webinar Click ’Raise Hand’ (preferred): or type your question into the Q&A box (alternative) Phone *6 - Toggle mute/unmute *9 - Raise hand 9
Slide 10: Appendix
Appendix 10
Slide 11: Publications
Publications Cotadutide Trial Journal Title Author Citation MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 Lancet 2018; 391: 2607- Phase II The Lancet Ambery, P et al. diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a stu
Slide 12: Publications, continued
Publications, continued AZD5718, continued Trial Journal Title Author Citation Novel chemical series of 5-Lipoxygenase-activating protein inhibitors Journal of Medicinal Chemistry Lemurell M et al. J. Med. Chem. 2019, 62, 9, 4325-4349. for treatment of coronary artery disease AZD4831 Safety, tolerab
Slide 13: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availabl